Search

everythinglearnresearchcommunity

for

Search:↓

The user shared a four-month hair growth progress using 1mg finasteride daily, 2.5mg oral minoxidil daily, and Hims thick fix shampoo every other day. Replies include comments on photo quality and lighting, a joke about the frequency of Hims product mentions, and the original poster humorously wishing for a Hims sponsorship.

Pelage is moving to Phase III clinical trials for PP405, a hair loss treatment, with results to be presented at a medical meeting. Users express skepticism and hope, comparing it to existing treatments like Minoxidil and finasteride, while discussing the potential for new hair growth in previously bald areas.

RU58841 may pose cancer risks due to its antiandrogen properties and lack of long-term safety data. Using it is considered a high-risk experiment with unknown potential for harm.

A user is pleased with their hair regrowth after 3 months using Minoxidil 5%. They plan to start Finasteride upon returning home, and others discuss the importance of consistency and patience with hair loss treatments.

There is no permanent cure for hair loss; treatments like finasteride, minoxidil, and hair transplants require ongoing use and are not universally effective. Genetic complexity and financial incentives for ongoing treatments hinder the development of a definitive cure.

Users discuss using pyrilutamide for hair loss, seeking alternatives to 5AR inhibitors. They mention using minoxidil, ketoconazole shampoo, and RU58841.

A user shared progress pictures showing hair regrowth after using 1mg finasteride daily, minoxidil foam twice daily, and dermarolling once a week for a year. Some commenters are skeptical about the authenticity of the before and after photos, joking about changes in appearance and questioning if it's the same person.

The conversation discusses whether to use finasteride for hair loss, considering its role in inhibiting DHT and 5AR, which can affect brain function and mood. Some users report anxiety and depression from finasteride, while others do not experience these side effects and emphasize the importance of DHT for brain and prostate health.

The release of a study on 5a-reductase inhibitors (finasteride and dutasteride) which showed an increased risk of depression, dementia, decreased libido, and reduced semen load as potential side effects; discussion around other forms of hair loss treatments such as topical minoxidil, RU58841, or opting to accept baldness; and advice to consider professional help for deeper issues related to hair loss.

The user's experience and success with taking finasteride to treat hair loss, which is confirmed by other users who have taken it without side effects. The user also advises that consulting a doctor before starting any kind of treatment for hair loss is important, as opposed to relying on self-made remedies available online.

Minoxidil and finasteride are the main treatments for hair loss, with Breezula and hair cloning being explored. No definitive cure is available yet.

The conversation discusses the safety study of PP405, emphasizing that early trials focus on safety rather than efficacy, and that any efficacy data from such a short study should be viewed skeptically. It also highlights that the information released is primarily for securing funding, and that meaningful efficacy results are expected in later phases.

Eirion Therapeutics is recruiting for phase 1 of ET-02 in Texas, which showed promising hair growth results in non-clinical studies. ET-02 demonstrated significantly more hair growth compared to Minoxidil.

A user is considering exosome therapy from Springs Rejuvenation for hair loss after unsuccessful attempts with PRP, adipose injections, and a laser cap. They are intrigued by the therapy's potential and the clinic's guarantee of 30% improved coverage, despite concerns about FDA approval and high-pressure sales tactics.

Serevelle is being considered for hair loss due to menopause, but its effectiveness is unclear. Minoxidil and hormone management are suggested alternatives.

The conversation discusses the use of finasteride for hair loss, comparing every day (ED) versus every other day (EOD) dosing. It suggests that both dosing schedules can be effective, but individual tolerance may vary.

SCUBE3 is available online but poses risks like tumor promotion and high costs. Users advise against using it due to health concerns and inefficacy as a standalone treatment.

The trial for TDM-105795 has been completed, and it was in phase 2A. The discussion seeks input on the next phases, 2B or 3, based on safety and efficacy.

The conversation discusses a clinical trial for Setipiprant in the US, starting June 29th, with eligibility excluding recent users of minoxidil or finasteride. It encourages informed decision-making before signing up.

The conversation discusses the importance of Finasteride for hair loss treatment in the EU and encourages individuals to voice their support to the EMA. It highlights the potential influence of public input on regulatory decisions.

The conversation is about using a topical hair loss treatment from eSurgery containing finasteride, minoxidil, and tretinoin. The user is seeking recommendations and experiences with this specific product.

People are discussing the anticipated release of PP405 phase 2a results, expected by the end of March, with some skepticism about its effectiveness. There is cautious optimism due to past experiences with similar treatments like Breezula, despite concerns about the lack of presentation at the AAD 2026 conference.

ET-02 showed significant hair growth in five weeks, outperforming minoxidil, with a non-hormonal mechanism that avoids side effects of treatments like finasteride. A phase 2 trial is planned to further assess ET-02's efficacy and safety.

PP405's phase 2a trial results were presented, focusing on safety and pharmacokinetics, with a future meeting planned to share the full dataset. The trial includes a randomized controlled portion and an open-label extension, with no indication of phase 2B completion.

Concerns about a potential ban on finasteride and dutasteride due to side effects, with users advocating for continued access and informed choice. Alternative treatments like pyrilutamide are also mentioned.

The conversation is about a user seeking help with hair regrowth treatments, specifically mentioning Setipiprant, Minoxidil, Finasteride, and RU58841. The user is trying to contact forum members for guidance on making and using these treatments.

The conversation discusses using estradiol mesotherapy to replicate hormone replacement therapy results while minimizing systemic exposure. It also covers the use of Spironolactone cream, which reportedly has no systemic side effects, and the potential risks of using bicalutamide and Spironolactone in men.

The conversation questions the lack of feedback on the effectiveness of PGE2 and setipiprant for hair loss, despite their availability. The user is puzzled by the absence of reviews or results, whether positive or negative.

The conversation discusses the removal of Breezula phase II 12-month results by Cassiopea and the search for the original data. Concerns were raised about potential negative long-term effects on hair growth, such as androgen receptor upregulation.

A user shared their 2-year progress using finasteride every other day with no side effects. Others discussed their experiences, shedding cycles, and patience with the treatment.